Increase in R&D activities in healthcare, surge in stringency of regulatory authorities concerning public healthcare welfare, and rise in adoption of in vitro model and early toxicity testing have boosted the growth of the early toxicity testing market. However, the limitations of preclinical testing hamper the market growth. On the contrary, technological advancements in the field …